{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T06:55:52Z","timestamp":1775544952397,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11864-025-01309-5","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:13:24Z","timestamp":1745993604000},"page":"476-485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Addressing Sexual Health in Breast Cancer Survivors: Evidence-Based Practices and Clinical Considerations"],"prefix":"10.1007","volume":"26","author":[{"given":"Laila S.","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"2","key":"1309_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102236","volume":"9","author":"MA Franzoi","year":"2024","unstructured":"Franzoi MA, Aupomerol M, Havas J, et al. Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes. ESMO Open. 2024;9(2): 102236. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102236.","journal-title":"ESMO Open"},{"issue":"6","key":"1309_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/pon.1947","volume":"21","author":"KE Flynn","year":"2012","unstructured":"Flynn KE, Reese JB, Jeffery DD, et al. Patient experiences with communication about sex during and after treatment for cancer. Psychooncology. 2012;21(6):594\u2013601. https:\/\/doi.org\/10.1002\/pon.1947.","journal-title":"Psychooncology"},{"key":"1309_CR3","doi-asserted-by":"publisher","unstructured":"Hanson A, Guglielmino J, Ormerod C, Katze N, Teteh D, Ericson M. Abstract PD8-07: the changing informational needs of young women affected by breast cancer: a national needs assessment. Cancer Res. 2023;83(5_Supplement):PD8-07.\u00a0https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-PD8-07.","DOI":"10.1158\/1538-7445.SABCS22-PD8-07"},{"issue":"3","key":"1309_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1188\/14.ONF.297-306","volume":"41","author":"M McCallum","year":"2014","unstructured":"McCallum M, Jolicoeur L, Lefebvre M, et al. Supportive care needs after gynecologic cancer: where does sexual health fit in? Oncol Nurs Forum. 2014;41(3):297\u2013306. https:\/\/doi.org\/10.1188\/14.ONF.297-306.","journal-title":"Oncol Nurs Forum"},{"issue":"12","key":"1309_CR5","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1002\/cncr.25832","volume":"117","author":"EK Hill","year":"2011","unstructured":"Hill EK, Sandbo S, Abramsohn E, et al. Assessing gynecologic and breast cancer survivors\u2019 sexual health care needs. Cancer. 2011;117(12):2643\u201351. https:\/\/doi.org\/10.1002\/cncr.25832.","journal-title":"Cancer"},{"issue":"1","key":"1309_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/SPC.0000000000000186","volume":"10","author":"SL Bober","year":"2016","unstructured":"Bober SL, Reese JB, Barbera L, et al. How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer. Curr Opin Support Palliat Care. 2016;10(1):44\u201354. https:\/\/doi.org\/10.1097\/SPC.0000000000000186.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"2","key":"1309_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11764-016-0577-9","volume":"11","author":"JB Reese","year":"2017","unstructured":"Reese JB, Sorice K, Beach MC, et al. Patient-provider communication about sexual concerns in cancer: a systematic review. J Cancer Surviv. 2017;11(2):175\u201388. https:\/\/doi.org\/10.1007\/s11764-016-0577-9.","journal-title":"J Cancer Surviv"},{"issue":"16_suppl","key":"1309_CR8","doi-asserted-by":"publisher","first-page":"11029","DOI":"10.1200\/JCO.2023.41.16_suppl.11029","volume":"41","author":"JB Reese","year":"2023","unstructured":"Reese JB, Bauman JR, Sorice KA, Middleton D, McIlhenny S, Bober SL. Hematology and oncology fellow education about sexual and reproductive health: a survey of program directors in the United States. JCO. 2023;41(16_suppl):11029\u201311029. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.11029.","journal-title":"JCO"},{"issue":"5","key":"1309_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1200\/JCO.2017.75.8995","volume":"36","author":"J Carter","year":"2018","unstructured":"Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American society of clinical oncology clinical practice guideline adaptation of cancer care Ontario guideline. J Clin Oncol. 2018;36(5):492\u2013511. https:\/\/doi.org\/10.1200\/JCO.2017.75.8995.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1309_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1200\/OP.20.00793","volume":"17","author":"EJ Cathcart-Rake","year":"2021","unstructured":"Cathcart-Rake EJ, Ruddy KJ, Bleyer A, Johnson RH. Breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncol Pract. 2021;17(6):305\u201313. https:\/\/doi.org\/10.1200\/OP.20.00793.","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"1309_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1200\/OP.20.01060","volume":"17","author":"RL Yung","year":"2021","unstructured":"Yung RL, Gralow JR. Time to focus on breast cancer in young adults. JCO Oncol Pract. 2021;17(6):314\u20136. https:\/\/doi.org\/10.1200\/OP.20.01060.","journal-title":"JCO Oncol Pract"},{"key":"1309_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/EDBK_100032","volume":"42","author":"A Katz","year":"2022","unstructured":"Katz A, Agrawal LS, Sirohi B. Sexuality after cancer as an unmet need: addressing disparities, achieving equality. Am Soc Clin Oncol Educ Book. 2022;42:11\u20137. https:\/\/doi.org\/10.1200\/EDBK_100032.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1309_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s13187-018-1438-1","volume":"35","author":"M Kano","year":"2020","unstructured":"Kano M, Sanchez N, Tam\u00ed-Maury I, Solder B, Watt G, Chang S. Addressing cancer disparities in SGM populations: recommendations for a national action plan to increase SGM health equity through researcher and provider training and education. J Canc Educ. 2020;35(1):44\u201353. https:\/\/doi.org\/10.1007\/s13187-018-1438-1.","journal-title":"J Canc Educ"},{"issue":"4","key":"1309_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jadpro.2019.10.4.6","volume":"10","author":"A Fehl","year":"2019","unstructured":"Fehl A, Ferrari S, Wecht Z, Rosenzweig M. Breast cancer in the transgender population. J Adv Pract Oncol. 2019;10(4):387\u201394. https:\/\/doi.org\/10.6004\/jadpro.2019.10.4.6.","journal-title":"J Adv Pract Oncol."},{"issue":"10","key":"1309_CR15","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1093\/oncolo\/oyad152","volume":"28","author":"CP Schr\u00f6der","year":"2023","unstructured":"Schr\u00f6der CP, van Leeuwen-Stok E, Cardoso F, et al. Quality of life in male breast cancer: prospective study of the international male breast cancer program (EORTC10085\/TBCRC029\/BIG2-07\/NABCG). Oncologist. 2023;28(10):e877\u201383. https:\/\/doi.org\/10.1093\/oncolo\/oyad152.","journal-title":"Oncologist."},{"key":"1309_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnbot.2020.00024","volume":"14","author":"ST Lindau","year":"2020","unstructured":"Lindau ST, Bensmaia SJ. Using bionics to restore sensation to reconstructed breasts. Front Neurorobot. 2020;14: 24. https:\/\/doi.org\/10.3389\/fnbot.2020.00024.","journal-title":"Front Neurorobot"},{"issue":"11","key":"1309_CR17","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1245\/s10434-017-5905-4","volume":"24","author":"JS Gass","year":"2017","unstructured":"Gass JS, Onstad M, Pesek S, et al. Breast-specific sensuality and sexual function in cancer survivorship: does surgical modality matter? Ann Surg Oncol. 2017;24(11):3133\u201340. https:\/\/doi.org\/10.1245\/s10434-017-5905-4.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"1309_CR18","doi-asserted-by":"publisher","first-page":"e1096","DOI":"10.1097\/SLA.0000000000005920","volume":"278","author":"K Diao","year":"2023","unstructured":"Diao K, Lei X, He W, et al. Patient-reported quality of life after breast-conserving surgery with radiotherapy versus mastectomy and reconstruction. Ann Surg. 2023;278(5):e1096\u2013102. https:\/\/doi.org\/10.1097\/SLA.0000000000005920.","journal-title":"Ann Surg"},{"issue":"6","key":"1309_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0631","volume":"157","author":"SE Hanson","year":"2022","unstructured":"Hanson SE, Lei X, Roubaud MS, et al. Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction. JAMA Surg. 2022;157(6): e220631. https:\/\/doi.org\/10.1001\/jamasurg.2022.0631.","journal-title":"JAMA Surg"},{"issue":"9","key":"1309_CR20","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1016\/j.bjps.2022.06.034","volume":"75","author":"JB Hammond","year":"2022","unstructured":"Hammond JB, Kandi LA, Armstrong VL, et al. Long-term breast and nipple sensation after nipple-sparing mastectomy with implant reconstruction: relevance to physical, psychosocial, and sexual well-being. J Plast Reconstr Aesthet Surg. 2022;75(9):2914\u20139. https:\/\/doi.org\/10.1016\/j.bjps.2022.06.034.","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"1","key":"1309_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/tbj.12542","volume":"22","author":"CH Wei","year":"2016","unstructured":"Wei CH, Scott AM, Price AN, et al. Psychosocial and sexual well-being following nipple-sparing mastectomy and reconstruction. Breast J. 2016;22(1):10\u20137. https:\/\/doi.org\/10.1111\/tbj.12542.","journal-title":"Breast J"},{"issue":"12","key":"1309_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000005437","volume":"11","author":"AW Peled","year":"2023","unstructured":"Peled AW, Von Eyben R, Peled ZM. Sensory outcomes after neurotization in nipple-sparing mastectomy and implant-based breast reconstruction. Plast Reconstr Surg - Global Open. 2023;11(12): e5437. https:\/\/doi.org\/10.1097\/GOX.0000000000005437.","journal-title":"Plast Reconstr Surg - Global Open"},{"issue":"11","key":"1309_CR23","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.1245\/s10434-023-13845-1","volume":"30","author":"MK Johnson","year":"2023","unstructured":"Johnson MK, Cortina CS, Hsu TL, et al. National trends in \u201cGoing Flat\u201d after mastectomy. Ann Surg Oncol. 2023;30(11):6374\u201382. https:\/\/doi.org\/10.1245\/s10434-023-13845-1.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1309_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12957-022-02515-3","volume":"20","author":"D Steffens","year":"2022","unstructured":"Steffens D, Kappos EA, Lunger A, et al. The double S technique to achieve aesthetic flat closure after conventional mastectomy. World J Surg Onc. 2022;20(1):42. https:\/\/doi.org\/10.1186\/s12957-022-02515-3.","journal-title":"World J Surg Onc"},{"issue":"22","key":"1309_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226723","volume":"11","author":"S Vegunta","year":"2022","unstructured":"Vegunta S, Kuhle CL, Vencill JA, Lucas PH, Mussallem DM. Sexual health after a breast cancer diagnosis: addressing a forgotten aspect of survivorship. JCM. 2022;11(22): 6723. https:\/\/doi.org\/10.3390\/jcm11226723.","journal-title":"JCM"},{"key":"1309_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.breast.2022.03.008","volume":"63","author":"WP Weber","year":"2022","unstructured":"Weber WP, Shaw J, Pusic A, et al. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy. The Breast. 2022;63:123\u201339. https:\/\/doi.org\/10.1016\/j.breast.2022.03.008.","journal-title":"The Breast"},{"issue":"2","key":"1309_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","volume":"20","author":"J Baumgart","year":"2013","unstructured":"Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause. 2013;20(2):162\u20138. https:\/\/doi.org\/10.1097\/GME.0b013e31826560da.","journal-title":"Menopause"},{"issue":"7","key":"1309_CR28","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","volume":"16","author":"J Bernhard","year":"2015","unstructured":"Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(15)00049-2.","journal-title":"Lancet Oncol"},{"key":"1309_CR29","doi-asserted-by":"publisher","unstructured":"Goldberg C, Greenberg MR, Noveihed A, et al. Ovarian suppression: early menopause, late effects. Curr Oncol Rep. Published online January 2, 2024. https:\/\/doi.org\/10.1007\/s11912-023-01491-5.","DOI":"10.1007\/s11912-023-01491-5"},{"key":"1309_CR30","unstructured":"FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer | FDA. Accessed April 25, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer"},{"issue":"3","key":"1309_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030619","volume":"16","author":"N Neupane","year":"2024","unstructured":"Neupane N, Bawek S, Gurusinghe S, et al. Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer. Cancers. 2024;16(3): 619. https:\/\/doi.org\/10.3390\/cancers16030619.","journal-title":"Cancers"},{"issue":"7","key":"1309_CR32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s11864-023-01079-y","volume":"24","author":"M Shastry","year":"2023","unstructured":"Shastry M, Hamilton E. Novel estrogen receptor-targeted agents for breast cancer. Curr Treat Options in Oncol. 2023;24(7):821\u201344. https:\/\/doi.org\/10.1007\/s11864-023-01079-y.","journal-title":"Curr Treat Options in Oncol"},{"key":"1309_CR33","doi-asserted-by":"publisher","unstructured":"Portman DJ, Gass MLS, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society. J Sex Med. 2014;11(12):2865\u20132872. https:\/\/doi.org\/10.1111\/jsm.12686.","DOI":"10.1111\/jsm.12686"},{"issue":"6","key":"1309_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/GME.0000000000001121","volume":"25","author":"SS Faubion","year":"2018","unstructured":"Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American menopause society and the International society for the study of women\u2019s sexual health. Menopause. 2018;25(6):596\u2013608. https:\/\/doi.org\/10.1097\/GME.0000000000001121.","journal-title":"Menopause"},{"issue":"1","key":"1309_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00520-020-05472-3","volume":"29","author":"J Carter","year":"2021","unstructured":"Carter J, Baser RE, Goldfrank DJ, et al. A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. Support Care Cancer. 2021;29(1):311\u201322. https:\/\/doi.org\/10.1007\/s00520-020-05472-3.","journal-title":"Support Care Cancer"},{"key":"1309_CR36","unstructured":"World Health Organization. Use and procurement of additional lubricants for male and female condoms: WHO\/UNFPA\/FHI: advisory note-key points. 2012. https:\/\/apps.who.int\/iris\/handle\/10665\/76580"},{"issue":"2","key":"1309_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/13697137.2015.1124259","volume":"19","author":"D Edwards","year":"2016","unstructured":"Edwards D, Panay N. Treating vulvovaginal atrophy\/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151\u201361. https:\/\/doi.org\/10.3109\/13697137.2015.1124259.","journal-title":"Climacteric"},{"issue":"1","key":"1309_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10549-016-3865-1","volume":"158","author":"M Hickey","year":"2016","unstructured":"Hickey M, Marino JL, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat. 2016;158(1):79\u201390. https:\/\/doi.org\/10.1007\/s10549-016-3865-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1309_CR39","doi-asserted-by":"publisher","unstructured":"ACOG Committee Opinion No. 659: The Use of Vaginal Estrogen in Women With a History of Estrogen-Dependent Breast Cancer. Obstet Gynecol. 2016;127(3):e93\u20136. https:\/\/doi.org\/10.1097\/AOG.0000000000001351.","DOI":"10.1097\/AOG.0000000000001351"},{"issue":"2","key":"1309_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","volume":"135","author":"I Le Ray","year":"2012","unstructured":"Le Ray I, Dell\u2019Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603\u20139. https:\/\/doi.org\/10.1007\/s10549-012-2198-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1309_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","volume":"6","author":"JE Dew","year":"2003","unstructured":"Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003;6(1):45\u201352.","journal-title":"Climacteric"},{"issue":"10","key":"1309_CR42","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djac112","volume":"114","author":"S Cold","year":"2022","unstructured":"Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a danish observational cohort study. JNCI: J National Cancer Inst. 2022;114(10):1347\u201354. https:\/\/doi.org\/10.1093\/jnci\/djac112.","journal-title":"JNCI: J National Cancer Inst"},{"issue":"3","key":"1309_CR43","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/AOG.0000000000005294","volume":"142","author":"P Agrawal","year":"2023","unstructured":"Agrawal P, Singh SM, Able C, et al. Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer. Obstet Gynecol. 2023;142(3):660\u20138. https:\/\/doi.org\/10.1097\/AOG.0000000000005294.","journal-title":"Obstet Gynecol"},{"key":"1309_CR44","doi-asserted-by":"publisher","unstructured":"McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. JAMA Oncol. 2023. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4508","DOI":"10.1001\/jamaoncol.2023.4508"},{"issue":"4","key":"1309_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/20533691231208473","volume":"29","author":"I Hussain","year":"2023","unstructured":"Hussain I, Talaulikar VS. A systematic review of randomised clinical trials \u2013 the safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors. Post Reprod Health. 2023;29(4):222\u201331. https:\/\/doi.org\/10.1177\/20533691231208473.","journal-title":"Post Reprod Health"},{"issue":"2","key":"1309_CR46","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/jnci\/djac211","volume":"115","author":"HJ Pederson","year":"2023","unstructured":"Pederson HJ, Faubion SS, Pruthi S, Goldfarb SRE. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. JNCI: J National Cancer Inst. 2023;115(2):220\u20131. https:\/\/doi.org\/10.1093\/jnci\/djac211.","journal-title":"JNCI: J National Cancer Inst"},{"issue":"3","key":"1309_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/GME.0000000000001463","volume":"27","author":"RJ Santen","year":"2020","unstructured":"Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361\u201370. https:\/\/doi.org\/10.1097\/GME.0000000000001463.","journal-title":"Menopause"},{"issue":"5","key":"1309_CR48","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/GME.0000000000000790","volume":"24","author":"DF Archer","year":"2017","unstructured":"Archer DF, Constantine GD, Simon JA, et al. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause. 2017;24(5):510\u20136. https:\/\/doi.org\/10.1097\/GME.0000000000000790.","journal-title":"Menopause"},{"issue":"7","key":"1309_CR49","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1200\/JOP.18.00710","volume":"15","author":"TA Sussman","year":"2019","unstructured":"Sussman TA, Kruse ML, Thacker HL, Abraham J. Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy. JOP. 2019;15(7):363\u201370. https:\/\/doi.org\/10.1200\/JOP.18.00710.","journal-title":"JOP"},{"key":"1309_CR50","doi-asserted-by":"publisher","unstructured":"Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer: Clinical Consensus. Obstet Gynecol. 2021;138(6):950\u2013960. https:\/\/doi.org\/10.1097\/AOG.0000000000004601.","DOI":"10.1097\/AOG.0000000000004601"},{"issue":"2","key":"1309_CR51","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00520-017-3878-2","volume":"26","author":"DL Barton","year":"2018","unstructured":"Barton DL, Sloan JA, Shuster LT, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(2):643\u201350. https:\/\/doi.org\/10.1007\/s00520-017-3878-2.","journal-title":"Support Care Cancer"},{"issue":"4","key":"1309_CR52","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00520-017-3960-9","volume":"26","author":"DL Barton","year":"2018","unstructured":"Barton DL, Shuster LT, Dockter T, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(4):1335\u201343. https:\/\/doi.org\/10.1007\/s00520-017-3960-9.","journal-title":"Support Care Cancer"},{"issue":"5","key":"1309_CR53","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/13697137.2022.2050208","volume":"25","author":"E Mension","year":"2022","unstructured":"Mension E, Alonso I, Cebrecos I, et al. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study. Climacteric. 2022;25(5):476\u201382. https:\/\/doi.org\/10.1080\/13697137.2022.2050208.","journal-title":"Climacteric"},{"issue":"5","key":"1309_CR54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/17446651.2019.1657008","volume":"14","author":"DF Archer","year":"2019","unstructured":"Archer DF, Simon JA, Portman DJ, Goldstein SR, Goldstein I. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. Expert Rev Endocrinol Metab. 2019;14(5):301\u201314. https:\/\/doi.org\/10.1080\/17446651.2019.1657008.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1309_CR55","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.maturitas.2019.04.143","volume":"124","author":"B Cai","year":"2019","unstructured":"Cai B, Djumaeva S, Kanakamedala H, Particco M, Altomare C. Incidence of breast cancer in VVA patients treated with ospemifene and those without any VVA related treatments from a us real-world data. Maturitas. 2019;124:162\u20133. https:\/\/doi.org\/10.1016\/j.maturitas.2019.04.143.","journal-title":"Maturitas"},{"key":"1309_CR56","unstructured":"Osphena [package insert]. Florham Park, NJ: Shionogi Inc.; 2019.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203505s015lbl.pdf."},{"issue":"2","key":"1309_CR57","doi-asserted-by":"publisher","first-page":"e2255706","DOI":"10.1001\/jamanetworkopen.2022.55706","volume":"6","author":"J Gunter","year":"2023","unstructured":"Gunter J. Genitourinary syndrome of menopause and the false promise of vaginal laser therapy. JAMA Netw Open. 2023;6(2):e2255706\u2013e2255706. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55706.","journal-title":"JAMA Netw Open"},{"key":"1309_CR58","unstructured":"Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women\u2019s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for \u201cvaginal rejuvenation\u201d | FDA.  https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims. Accessed April 24, 2024."},{"key":"1309_CR59","doi-asserted-by":"publisher","unstructured":"Mension E, Alonso I, Angl\u00e8s-Acedo S, et al. Effect of fractional carbon dioxide vs sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: the LIGHT randomized clinical trial. JAMA Netw Open. 2023;6(2):e2255697\u2013e2255697. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.55697.","DOI":"10.1001\/jamanetworkopen.2022.55697"},{"issue":"30","key":"1309_CR60","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1200\/JCO.2014.60.7366","volume":"33","author":"MF Goetsch","year":"2015","unstructured":"Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394\u2013400. https:\/\/doi.org\/10.1200\/JCO.2014.60.7366.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1309_CR61","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/0092623X.2022.2154296","volume":"49","author":"C Sears","year":"2023","unstructured":"Sears C, Millman R, Brotto LA, Walker LM. Feasibility and acceptability of a group-based mindfulness Intervention for sexual interest\/arousal disorder following breast cancer treatment. J Sex Marital Ther. 2023;49(5):533\u201349. https:\/\/doi.org\/10.1080\/0092623X.2022.2154296.","journal-title":"J Sex Marital Ther"},{"issue":"6","key":"1309_CR62","first-page":"402","volume":"22","author":"JA Albaugh","year":"2002","unstructured":"Albaugh JA, Kellogg-Spadt S. Sensate focus and its role in treating sexual dysfunction. Urol Nurs. 2002;22(6):402\u20133.","journal-title":"Urol Nurs"},{"issue":"4","key":"1309_CR63","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.21.01473","volume":"40","author":"DL Barton","year":"2022","unstructured":"Barton DL, Pugh SL, Ganz PA, et al. Randomized controlled phase II evaluation of two dose levels of Bupropion versus Placebo for sexual desire in female cancer survivors: NRG-CC004. JCO. 2022;40(4):324\u201334. https:\/\/doi.org\/10.1200\/JCO.21.01473.","journal-title":"JCO"},{"issue":"2","key":"1309_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1056\/NEJMp1513686","volume":"374","author":"HV Joffe","year":"2016","unstructured":"Joffe HV, Chang C, Sewell C, et al. FDA approval of flibanserin \u2014 treating hypoactive sexual desire disorder. N Engl J Med. 2016;374(2):101\u20134. https:\/\/doi.org\/10.1056\/NEJMp1513686.","journal-title":"N Engl J Med"},{"key":"1309_CR65","doi-asserted-by":"publisher","unstructured":"Goldfarb SB, Carter J, Arkema A, et al. Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy. JCO. 2023;41(16_suppl):12015\u201312015. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.12015.","DOI":"10.1200\/JCO.2023.41.16_suppl.12015"},{"issue":"5","key":"1309_CR66","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/AOG.0000000000003500","volume":"134","author":"SA Kingsberg","year":"2019","unstructured":"Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899\u2013908. https:\/\/doi.org\/10.1097\/AOG.0000000000003500.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"1309_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18041640","volume":"18","author":"L Morales-S\u00e1nchez","year":"2021","unstructured":"Morales-S\u00e1nchez L, Luque-Ribelles V, Gil-Olarte P, Ruiz-Gonz\u00e1lez P, Guil R. Enhancing self-esteem and body image of breast cancer women through interventions: a systematic review. Int J Environ Res Public Health. 2021;18(4): 1640. https:\/\/doi.org\/10.3390\/ijerph18041640.","journal-title":"Int J Environ Res Public Health"},{"key":"1309_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.611954","volume":"12","author":"V Sebri","year":"2021","unstructured":"Sebri V, Durosini I, Triberti S, Pravettoni G. The efficacy of psychological intervention on body image in breast cancer patients and survivors: a systematic-review and meta-analysis. Front Psychol. 2021;12: 611954. https:\/\/doi.org\/10.3389\/fpsyg.2021.611954.","journal-title":"Front Psychol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01309-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01309-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T06:27:20Z","timestamp":1748672840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01309-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1309"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01309-5","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}